Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer von Rubio Pérez, María Jesús 

Volltext

Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial von Callens, Celine, Rodrigues, Manuel, Briaux, Adrien, Frouin, Eleonore, Eeckhoutte, Alexandre, Pujade-Lauraine, Eric, Renault, Victor, Stoppa-Lyonnet, Dominique, Bieche, Ivan, Bataillon, Guillaume, Karayan-Tapon, Lucie, Rochelle, Tristan, Heitz, Florian, Cecere, Sabrina Chiara, Pérez, Maria Jesús Rubio, Grimm, Christoph, Nøttrup, Trine Jakobi, Colombo, Nicoletta, Vergote, Ignace, Yonemori, Kan, Ray-Coquard, Isabelle, Stern, Marc-Henri, Popova, Tatiana

Volltext

Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy von Vulsteke, Christof, Chambers, Setsuko K., Pérez, Maria Jesús Rubio, Chan, John K., Raaschou-Jensen, Nicoline, Zhuo, Ying, Lorusso, Domenica, Herzog, Thomas J., de la Motte Rouge, Thibault, Thomes Pepin, Jessica A., Braicu, Elena Ioana, Chen, Lee-may, Levy, Tally, Barter, James F., Pilar Barretina-Ginesta, M., Joosens, Eric, York, Whitney, Malinowska, Izabela A., González-Martín, Antonio, Monk, Bradley J.

Volltext

SEOM–GEICO clinical guideline on epithelial ovarian cancer (2023) von Perez-Fidalgo, Jose Alejandro, Gálvez-Montosa, Fernando, Guerra, Eva María, Madariaga, Ainhoa, Manzano, Aranzazu, Martin-Lorente, Cristina, Rubio-Pérez, Maria Jesús, Alarcón, Jesus, Barretina-Ginesta, María Pilar, Gaba, Lydia

Volltext

SEOM-GEICO clinical guidelines on endometrial cancer (2021) von Barretina-Ginesta, María Pilar, Quindós, María, Alarcón, Jesús Damián, Esteban, Carmen, Gaba, Lydia, Gómez, César, Fidalgo, José Alejandro Pérez, Romero, Ignacio, Santaballa, Ana, Rubio-Pérez, María Jesús

Volltext

BEATcc (ENGOT-CX10/GEICO 68-C/JGOG-1084/GOG-3030): A randomized phase III trial of first-line atezolizumab with bevacizumab and platinum-based chemotherapy for metastatic (stage IV... von Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Ortiz, Ana Godoy, Nishio, Shin, Rubio-Pérez, Maria Jesús, Yamaguchi, Satoshi, Lorusso, Domenica, Randall, Leslie

Volltext

Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer wi... von Harter, Philipp, Wimberger, Pauline, Okamoto, Aikou, Reuss, Alexander, Lim, Myong Cheol, Rubio-Pérez, Maria Jesús, Vardar, Mehmet Ali, Scambia, Giovanni, Trédan, Olivier, Hietanen, Sakari, Colombo, Nicoletta, Chudecka-Glaz, Anita, Petru, Edgar, Lheureux, Stephanie, Van Nieuwenhuysen, Els, Sehouli, Jalid, Wenham, Robert, Ushijima, Kimio, Indiviglio, Sandra, Aghajanian, Carol

Volltext

Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred du... von Harter, Philipp, Mouret-Reynier, Marie-Ange, Lorusso, Domenica, Cropet, Claire, Guerra, Eva M., Wolfrum-Ristau, Pia, Matsumoto, Takashi, Vergote, Ignace, Colombo, Nicoletta, Maenpaa, Johanna Unelma, Lebreton, Coriolan, de Gregorio, Nikolaus, Mosconi, Anna Maria, Rubio-Pérez, Maria Jesús, Bourgeois, Hugues, Fasching, Peter A., Hardy-Bessard, Anne-Claire, Denschlag, Dominik, Pujade-Lauraine, Eric, Ray-Coquard, Isabelle Laure

Volltext

Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian can... von Harter, Philipp, Trillsch, Fabian, Okamoto, Aikou, Reuss, Alexander, Kim, Jae-Weon, Rubio-Pérez, Maria Jesús, Vardar, Mehmet Ali, Scambia, Giovanni, Tredan, Olivier, Nyvang, Gitte-Bettina, Colombo, Nicoletta, Chudecka-Głaz, Anita M., Grimm, Christoph, Lheureux, Stephanie, Van Nieuwenhuysen, Els, Heitz, Florian, Wenham, Robert M., Ushijima, Kimio, Day, Emily, Aghajanian, Carol

Volltext

LIO-1: Initial phase 2 experience of lucitanib + nivolumab in patients with metastatic or recurrent cervical cancer (NCT04042116; ENGOT-GYN3/AGO/LIO) (034) von Oaknin, Ana, Backes, Floor, Nieuwenhuysen, Els Van, Eskander, Ramez, González-Martín, Antonio, Makker, Vicky, Marth, Christian, Patel, Manish, Penson, Richard, Redondo, Andrés, Pérez, Maria Jesús Rubio, Hamilton, Erika, Concin, Nicole, McNees, Alexander, Wride, Kenton, Lepley, Denise, Dusek, Rachel, Cameron, Terri, Pignata, Sandro

Volltext

A randomized Phase III trial of durvalumab with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cance... von Okamoto, Aikou, Kim, Jae-Weon, Yin, Rutie, Trillsch, Fabian, Reuss, Alexander, Aghajanian, Carol, Rubio-Pérez, Maria Jesús, Vardar, Mehmet Ali, Scambia, Giovanni, Floquet, Anne, Nyvang, Gitte-Bettina, Colombo, Nicoletta, Bidzinski, Mariusz, Marth, Christian, Lheureux, Stéphanie, Van Nieuwenhuysen, Els, Rugman, Paul, Wessen, Jonathan, Harter, Philipp

Volltext

DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly d... von Harter, Philipp, Bidziński, Mariusz, Colombo, Nicoletta, Floquet, Anne, Rubio Pérez, Maria Jesús, Kim, Jae-Weon, Lheureux, Stephanie, Marth, Christian, Nyvang, Gitte-Bettina, Okamoto, Aikou, Reuss, Alexander, Scambia, Giovanni, Trillsch, Fabian, Vardar, Mehmet Ali, Van Nieuwenhuysen, Els, Lichfield, Jasmine, Rugman, Paul, Twumasi-Ankrah, Philip, Aghajanian, Carol

Volltext

Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analys... von Poveda, Andres, Lheureux, Stephanie, Colombo, Nicoletta, Cibula, David, Lindemann, Kristina, Weberpals, Johanne I, Bjurberg, Maria, Oaknin, Ana, Sikorska, Magdalena, Gonzalez Martin, Antonio, Madry, Radoslaw, Rubio Pérez, Maria Jesus, Davidson, Richard, Blakeley, Christopher, Bennett, James, Barnicle, Alan, Skof, Erik

Volltext

A nomogram to predict progression-free survival benefit with maintenance olaparib and bevacizumab following response to first line chemotherapy in advanced ovarian cancer (305) von Lee, Chee, Gebski, Val, Francis, Katherine, Grenier, Julien, Welz, Julia, Mosconi, Anna Maria, Rubio-Perez, Maria Jesús, Grimm, Christoph, Matsumoto, Takashi, Vergote, Ignace, Colombo, Nicoletta, Mirza, Mansoor Raza, FOLLANA, Philippe, de Gregorio, Nikolaus, Zamagni, Claudio, García-García, Yolanda, Meunier, Jérôme, Pujade-Lauraine, Eric, Friedlander, Michael, Ray-Coquard, Isabelle

Volltext

ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer von Marth, Christian, Vulsteke, Christof, Rubio Pérez, Maria Jesus, Makker, Vicky, Braicu, Elena Ioana, McNeish, Iain A., Madry, Radoslaw, Ayhan, Ali, Hasegawa, Kosei, Wu, Xiaohua, Dutta, Lea, Xu, Cindy, Keefe, Stephen Michael, Lee, John J., Pignata, Sandro

Volltext

Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by... von Lorusso, Domenica, Lotz, Jean-Pierre, Harter, Philipp, Cropet, Claire, Rubio Pérez, Maria Jesus, Schauer, Christian, Matsumoto, Takashi, Vergote, Ignace, Colombo, Nicoletta, Noettrup, Trine Jakobi, Bourgeois, Hugues Pierre, Schnelzer, Andreas, Pignata, Sandro, Garcia, Yolanda, Provansal, Magali, Hanker, Lars Christian, Berton, Dominique, Bauerschlag, Dirk, Joly, Florence, Ray-Coquard, Isabelle Laure

Volltext

Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil von Morales Chamorro, Rafael, Serrano Blanch, Raquel, Méndez Vidal, María José, Gómez España, María Auxiliadora, Rubio Pérez, María Jesús, de la Haba Rodríguez, Juan Rafael, Aranda Aguilar, Enrique

Volltext

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/... von Colombo, N., Gadducci, A., Sehouli, J., Rulli, E., Mäenpää, J., Sessa, C., Montes, A., Ottevanger, N. B., Berger, R., Vergote, I., D’Incalci, M., Churruca Galaz, C., Chekerov, R., Nyvang, G. B., Riniker, S., Herbertson, R., Fossati, R., Barretina-Ginesta, M. P., Deryal, M., Mirza, M. R., Biagioli, E., Iglesias, M., Funari, G., Romeo, M., Tasca, G., Pardo, B., Tognon, G., Rubio-Pérez, M. J., DeCensi, A., De Giorgi, U., Zola, P., Benedetti Panici, P., Aglietta, M., Arcangeli, V., Zamagni, C., Bologna, A., Westermann, A., Heinzelmann-Schwarz, V., Tsibulak, I., Wimberger, P., Poveda, A.

Volltext

Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial von Callens, Celine, Rodrigues, Manuel, Briaux, Adrien, Frouin, Eleonore, Eeckhoutte, Alexandre, Pujade-Lauraine, Eric, Renault, Victor, Stoppa-Lyonnet, Dominique, Bieche, Ivan, Bataillon, Guillaume, Karayan-Tapon, Lucie, Rochelle, Tristan, Heitz, Florian, Cecere, Sabrina Chiara, Perez, Maria Jesus Rubio, Grimm, Christoph, Nottrup, Trine Jakobi, Colombo, Nicoletta, Vergote, Ignace, Yonemori, Kan, Ray-Coquard, Isabelle, Stern, Marc-Henri, Popova, Tatiana

Volltext

Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer von Rubio Pérez, María Jesús

Volltext